Bolt Biotherapeutics logo

Bolt BiotherapeuticsNASDAQ: BOLT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 February 2021

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$25.21 M
-94%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
22%vs. sector
-99%vs. 3y high
40%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:47:41 GMT
$0.66+$0.02(+3.39%)

Dividend

No data over the past 3 years
$1.27 M$1.26 M
$1.27 M-$21.20 M

Analysts recommendations

Institutional Ownership

BOLT Latest News

Bolt Biotherapeutics Announces Changes to its Board of Directors
globenewswire.com04 September 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
prnewswire.com03 September 2024 Sentiment: NEGATIVE

NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and certain officers.

The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit
accesswire.com03 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com03 September 2024 Sentiment: NEGATIVE

LOS ANGELES , Sept. 3, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
businesswire.com02 September 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024. Bolt describes itself as a “clinical-stage biopharmaceutical company, [that] engages in the development of immunotherapies for the treatment of cancer.” For more information, submit a form, email attorney Phillip Kim, or give us a ca.

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions
accesswire.com02 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.

IMMINENT BOLT DEADLINE to Actively Participate in the Class Action Lawsuit for Bolt Biotherapeutics, Inc.: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Last Few Hours!
accesswire.com02 September 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / September 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").

A Securities Fraud Lawsuit Has Been Filed On Behalf Of Investors In Bolt Biotherapeutics Inc And The Schall Law Firm Wants Affected Investors To Reach Out
accesswire.com01 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
accesswire.com01 September 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BOLT
accesswire.com01 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

What type of business is Bolt Biotherapeutics?

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

What sector is Bolt Biotherapeutics in?

Bolt Biotherapeutics is in the Healthcare sector

What industry is Bolt Biotherapeutics in?

Bolt Biotherapeutics is in the Biotechnology industry

What country is Bolt Biotherapeutics from?

Bolt Biotherapeutics is headquartered in United States

When did Bolt Biotherapeutics go public?

Bolt Biotherapeutics initial public offering (IPO) was on 05 February 2021

What is Bolt Biotherapeutics website?

https://www.boltbio.com

Is Bolt Biotherapeutics in the S&P 500?

No, Bolt Biotherapeutics is not included in the S&P 500 index

Is Bolt Biotherapeutics in the NASDAQ 100?

No, Bolt Biotherapeutics is not included in the NASDAQ 100 index

Is Bolt Biotherapeutics in the Dow Jones?

No, Bolt Biotherapeutics is not included in the Dow Jones index

When was Bolt Biotherapeutics the previous earnings report?

No data

When does Bolt Biotherapeutics earnings report?

The next expected earnings date for Bolt Biotherapeutics is 08 November 2024